This category covers biotechnology and pharmaceutical companies developing therapies targeting metal dyshomeostasis and oxidative stress in Alzheimer's disease. These approaches address two interconnected pathological features that are increasingly recognized as central drivers of neurodegeneration: the disruption of copper, zinc, and iron homeostasis in the brain, and the consequent generation of reactive oxygen species that damage neurons, proteins, and cellular structures.
Metal dyshomeostasis is one of the earliest detectable abnormalities in Alzheimer's disease, often preceding clinical symptoms by decades. Elevated iron accumulates in specific brain regions, copper homeostasis becomes disrupted, and zinc signaling is altered. These metal abnormalities contribute to amyloid-beta aggregation, tau phosphorylation, oxidative stress generation, and neuroinflammation. Simultaneously, the aging brain faces declining antioxidant capacity, leading to a vicious cycle of oxidative damage and neuronal dysfunction["@metal_ad_review"][@oxidative_ad].
Companies in this space pursue diverse mechanisms including direct metal chelation, antioxidant therapies, metal homeostasis modulation, and metabolic approaches that indirectly reduce oxidative stress. Unlike traditional approaches focused solely on amyloid or tau, these therapies aim to correct fundamental cellular dysfunctions that underlie multiple pathological features of AD.
Key Companies
Metal Homeostasis Modulation
Aleza Therapeutics
Focus: TREM2 activation and copper/zinc homeostasis modulation
Lead Candidate: AZT-101 (TREM2 agonist)
Indication: Early Alzheimer's disease
Stage: Phase IIa
Mechanism: TREM2 agonism enhances microglial phagocytosis and modulates metal ion handling in the brain
Notes: Oral small molecule approach differentiating from antibody therapies; addresses both amyloid clearance and neuroinflammation through microglial modulation
Mechanism: Inhibits glutaminyl cyclase (QC) to prevent formation of pGlu-modified amyloid-beta, which exhibits enhanced metal-binding and aggregation properties
Notes: Unique mechanism targeting N-terminal pyroglutamate modification that increases Aβ metal affinity and neurotoxicity; demonstrated target engagement in Phase IIa (SAPIR trial)
Mechanism: Oral iron chelator that can cross the blood-brain barrier and reduce brain iron stores
Notes: Primarily focused on Parkinson's disease (FAIRPARK trials); investigating applicability to AD where iron accumulation also occurs
Page: [Apopharma Inc.](/companies/apopharma)
Antioxidant and Mitochondrial Protection
MitoThera
Focus: Mitochondria-targeted antioxidants
Lead Candidate: MT-101
Indication: Alzheimer's disease (exploratory)
Stage: Discovery
Mechanism: Uses triphenylphosphonium (TPP) cation to deliver antioxidants directly to mitochondrial matrix; catalytically regenerated by electron transport chain
Notes: Primarily focused on Parkinson's disease; mitochondrial oxidative stress is a shared feature in AD
Page: [MitoThera](/companies/mitothera)
Additional Companies in Related Space
| Company | Focus | Mechanism | Stage | Notes | |---------|-------|-----------|-------|-------| | Alterity Therapeutics | Protein aggregation with metal-binding | Quinazolinone small molecules with metal interaction | Phase 1 (PD) | Originally developed PBT2 for AD; shifted to PD focus | | Nobelpharma | Rare neurological diseases | Various mechanisms | Multiple | Japanese company focused on orphan neurological conditions |
Therapeutic Mechanisms
Metal Chelation Approaches
Iron Chelation: Reducing brain iron accumulation through chelators that can cross the blood-brain barrier. Iron dysregulation contributes to oxidative stress through Fenton chemistry and promotes amyloid aggregation.
Copper Modulation: Normalizing copper homeostasis which is disrupted in AD. Copper interacts with amyloid-beta and influences its aggregation behavior and neurotoxicity.
Zinc Homeostasis: Modulating zinc signaling which affects synaptic function and amyloid processing. Zinc dyshomeostasis is implicated in early cognitive decline.
Antioxidant Approaches
Direct Antioxidants: Scavenging reactive oxygen species (ROS) in the brain. Challenges include achieving therapeutic concentrations in the CNS and avoiding pro-oxidant effects.
Mitochondria-Targeted Antioxidants: Delivering antioxidants directly to mitochondria using lipophilic cations (TPP, MitoQ) that accumulate in the mitochondrial matrix.
Endogenous Antioxidant Enhancement: Upregulating natural antioxidant systems including Nrf2 pathway activation, superoxide dismutase, and glutathione synthesis.
Metabolic Approaches
PPAR Agonism: Peroxisome proliferator-activated receptor activation improves brain energy metabolism, reduces neuroinflammation, and indirectly reduces oxidative stress.
GLUT1 Facilitators: Enhancing glucose transport across the blood-brain barrier to support neuronal energy needs and reduce metabolic stress.
Scientific Rationale
Metal Dyshomeostasis in AD
The role of metal dyshomeostasis in Alzheimer's disease is supported by multiple lines of evidence:
Iron Dysregulation:
Increased iron in specific brain regions (hippocampus, basal ganglia) as early as MCI
Ferritin elevation in CSF correlates with disease progression
Iron promotes amyloid-beta aggregation through Fenton chemistry
Iron accumulation in microglia correlates with disease severity[@metal_ad_review]
Copper Homeostasis:
Serum copper alterations in AD patients
Copper interacts with amyloid-beta to form toxic complexes
Ceruloplasmin abnormalities in AD
Copper deficiency in brain despite systemic accumulation[@copper_zinc_ad]
Zinc Signaling:
Altered zinc transporter expression in AD brain
Zinc modulates amyloid-beta aggregation
Zinc deficiency affects synaptic function
Zinc supplementation trials show mixed results
Oxidative Stress in AD
Oxidative damage is one of the earliest detectable features of AD:
Increased lipid peroxidation markers (4-HNE, MDA)
Protein oxidation (carbonylated proteins)
DNA oxidation (8-OHdG)
Mitochondrial DNA mutations accumulate
Antioxidant systems decline with age and in AD[@oxidative_ad]
The brain's high oxygen consumption, lipid-rich environment, and limited regenerative capacity make it particularly vulnerable to oxidative damage.
Pipeline Summary
| Company | Drug | Mechanism | Phase | Indication | |---------|------|-----------|-------|-------------| | Aleza Therapeutics | AZT-101 | TREM2 agonist/copper-zinc modulation | Phase IIa | Early AD | | Vivoryon | Varoglutamstat | QC inhibitor | Phase IIb | Early AD | | T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Phase 2 | AD | | Apopharma | Deferiprone | Iron chelation | Research | AD | | MitoThera | MT-101 | Mitochondria-targeted antioxidant | Discovery | AD |
Clinical Development Considerations
Biomarkers for Patient Selection
Key biomarkers being developed to enrich patient populations:
Iron markers: Serum ferritin, CSF ferritin, MRI R2*